Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00661_DB01201_nanopub.RAHDRtU1gwIf6xIybr8B6bZmWR1QsZ7eti6tvlY2BGTus#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00661_DB01201 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00661_DB01201 label "DDI between Verapamil and Rifapentine - Rifapentine, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifapentine is initiated, discontinued or dose changed. [drugbank_resource:DB00661_DB01201]" assertion.
- drugbank_resource:DB00661_DB01201 identifier "drugbank_resource:DB00661_DB01201" assertion.
- drugbank_resource:DB00661_DB01201 title "DDI between Verapamil and Rifapentine - Rifapentine, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifapentine is initiated, discontinued or dose changed." assertion.
- drugbank:DB00661 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00661_DB01201 assertion.
- drugbank:DB01201 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00661_DB01201 assertion.